Skip to content
RNAWiki

Tocilizumab-Aazg

  • Biologic
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Tocilizumab-Aazg does in the body

1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis.

Why people take it. TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as protein.

    FDA substance registry · I031V2H011 · read 2026-08-29

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 180 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Formulation

A formulation is the exact made-up form a substance comes in.

A picture of it, and where the picture fails

It is like the difference between a whole bean and instant coffee.

Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.

What people get wrong. Two products with the same name are assumed to behave the same. They often do not.

The specific composition and physical form of a product, including salt, excipients and release profile.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Number of participants with elevation of liver transaminases

The study did not show it

Who was studied
NCT06863480
How many people
30
Study design
Phase 1
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • FDA nonproprietary naming guidance for biological products · a recorded source, not a stored snapshot
What we know
RNAWiki holds 1 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Moderately to severely active rheumatoid arthritis who have had an inadequate respon

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness in pediatric patients below the age of 2 have not been established in PJIA, SJIA, CRS or COVID-19.”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

  • On older people, the label states: “Clinical studies that included tocilizumab for CRS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary The available data with tocilizumab products from a pregnancy exposure registry, retrospective cohort study, pharmacovigilance, and published literature are insufficient to draw conclusions about a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary No information is available on the presence of tocilizumab products in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

  • On people with reduced liver function, the label states: “The safety and efficacy of tocilizumab products have not been studied in patients with hepatic impairment, including patients with positive HBV and HCV serology [see Warnings and Precautions ( 5.8 )] .”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

  • On people with reduced kidney function, the label states: “No dose adjustment is required in patients with mild or moderate renal impairment.”

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

A different form was studied

The studied form is not the form on the shelf.

On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No form or route is recorded.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S1, S6.

No source is stored against this line.

What is in the pack

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing is recorded about product quality.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

The exact form studied is not recorded.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 3 published labels name it as an active ingredient. 3 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-29

  • TYENNE is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Intravenous Infusion Injection: 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL) in single-dose vials for further dilution prior to intravenous infusion ( 3 ) Subcutan…, recorded as fda label in effect 2026-07-23 in the United States.

    US prescribing information · 87ac5047-4f2b-4571-a8a8-32e08865f379 · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

Names and forms linked to this record

  • Biosimilar of

    Tocilizumab

    Evidence on this page does not automatically apply to this one.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Tocilizumab-Aazg studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Tocilizumab-Aazg are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 3 documents were read for this substance.

    RNAWiki source record

  • 3 of them state the same halfLife, and they agree.

    RNAWiki source record

  • 3 of them state the same bioavailability, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
I031V2H011
RxNorm concept
2686045

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S1, S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 2 approved applications cover products containing this substance. The earliest was BLA761275, approved 20240305 to FRESENIUS KABI USA.

    Drugs@FDA application register · BLA761275 · read 2026-08-29

  • Marketing status on the register: prescription.

    Drugs@FDA application register · BLA761275 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (8)

On the Tocilizumab-Aazg label: indicated for what?

"TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant…": indications and usage on Tocilizumab-Aazg's label. DailyMed label · 87ac5047-4f2b-4571-a8a8-32e08865f379 · 2026-07-23

135 registered trials of Tocilizumab-Aazg — at which phases?

Registered studies posting no result
81 of 135

135 registered studies of Tocilizumab-Aazg: 54 phase2, 36 phase1, 28 phase3, 14 na or unstated, 13 phase4, 3 na, 2 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01

0 with a PubMed record

Show the evidence
  • phase2
    54
  • phase1
    36
  • phase3
    28
  • na or unstated
    14
  • phase4
    13
  • na
    3
8 more recorded rows
  • early phase1
    2
  • completed
    66
  • terminated
    19
  • recruiting
    17
  • active not recruiting
    14
  • unknown
    11
  • withdrawn
    7
  • not yet recruiting
    1

recorded 2026-09-01 · last checked 2026-09-04

24 of Tocilizumab-Aazg's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?

safety (3), futility/efficacy (1), accrual/recruitment (9), funding/business (4) and other (7): Tocilizumab-Aazg's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Tocilizumab was licenced in Canada for children, so the study was not necessary"; 24 of 135 registered studies

Show the evidence

Trial

  • NCT01104480
    withdrawn; "Tocilizumab was licenced in Canada for children, so the study was not necessary"
  • NCT01209689
    terminated; "Clinical development program terminated due to failure to achieve efficacy"
  • NCT01475162
    terminated; "The DSMB felt the risks of the study now outweighed the potential benefits."
  • NCT01603355
    terminated; "insufficient enrollment"
  • NCT01693653
    terminated; "low enrollment"
  • NCT01757197
    terminated; "Slow accrual"
14 further recorded trials
  • NCT02057770
    terminated; "Low accrual rate"
  • NCT02174263
    withdrawn; "Study never opened due to lack of funds."
  • NCT02353780
    terminated; "Low enrollment"
  • NCT02511067
    withdrawn; "Funding lost and study never started"
  • NCT02659150
    terminated; "Terminated by sponsor owing to slow enrollment"
  • NCT02660528
    terminated; "Study staff change."
  • NCT02997956
    withdrawn; "funding issues"
  • NCT03588936
    terminated; "Poor accrual and loss of funding."
  • NCT04070781
    terminated; "The primary reason for study closure is slow enrollment."
  • NCT04335071
    terminated; "1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no…"
  • NCT04335305
    terminated; "Recruitment issues"
  • NCT04361552
    withdrawn; "Study abandoned due to drug billing issues"
  • NCT04370834
    terminated; "Other - Randomized data no longer support continuation"
  • NCT04403685
    terminated; "Safety"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Tocilizumab-Aazg used Tocilizumab 20 MG/ML [Actemra] — over how long?

studies of Tocilizumab-Aazg used the recorded amount. ClinicalTrials.gov · 2026-09-01

1 recorded entry; human; also "Tocilizumab 20 MG/ML [Actemra]"

Show the evidence
  • human NCT06426160
    Tocilizumab 20 MG/ML [Actemra]

recorded 2026-09-01 · last checked 2026-09-04

Tocilizumab-Aazg's half-life is 21.5 days — which schedules were studied?

21.5 days, the half-life Tocilizumab-Aazg's label states: "At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates." DailyMed label · 87ac5047-4f2b-4571-a8a8-32e08865f379 · 2026-07-23

tmax 2.8 days; bioavailability 80 %.

Show the evidence
  • half life pharmacokinetics
    21.5 days; At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
  • tmax pharmacokinetics
    2.8 days; In RA patients the median values of T max were 2.8 days after the tocilizumab every week dose and 4.7 days after the tocilizumab every other week dose.
  • bioavailability pharmacokinetics
    80 %; The bioavailability for the subcutaneous formulation was 80%.
  • metabolism pharmacokinetics
    Accordingly, inhibition of IL-6 signaling in RA patients treated with tocilizumab may restore CYP450 activities to higher levels than those in the absence of tocilizumab leading to increased metabolism of drugs that are CYP450 substrates.

recorded 2026-07-23 · last checked 2026-09-04

Which 22 trials of Tocilizumab-Aazg posted no result?

Posted no result
22 of 22 completed trials
Registrations
NCT01120366, NCT02797769, NCT01455701, NCT03062579, NCT02648035 and NCT03522012, and 16 more
Completion dates
oldest 2014-12; newest 2024-06-11
Show the evidence

Trial

  • NCT01120366
    2014-12
  • NCT02797769
    2016-06-02
  • NCT01455701
    2017-07-13
  • NCT03062579
    2018-05-15
  • NCT02648035
    2018-12-20
  • NCT03522012
    2018-12-20
14 further recorded trials
  • NCT03533101
    2019-06-15
  • NCT03606876
    2019-07-17
  • NCT03350633
    2019-09-01
  • NCT03282851
    2019-10-01
  • NCT03263715
    2020-06-02
  • NCT04873141
    2020-06-22
  • NCT03446209
    2020-10-30
  • NCT03830203
    2021-01-05
  • NCT05302947
    2021-06-30
  • NCT04734678
    2021-08-01
  • NCT04551352
    2022-07-28
  • NCT06481202
    2022-08-19
  • NCT04871854
    2022-08-26
  • NCT04885829
    2023-05-04

At the median, Tocilizumab-Aazg's trials enrolled 50 people — anything larger?

Median enrolment
50
Largest enrolment
48950
Registered trials counted
135

Tocilizumab-Aazg and CYP3A4, CYP1A2 and CYP2B6: shared by which compounds?

CYP3A4, CYP1A2 and CYP2B6 appear in Tocilizumab-Aazg's recorded interaction sentences, 8 in all. DailyMed label · 87ac5047-4f2b-4571-a8a8-32e08865f379 · 2026-07-23

CYP1A2, CYP2B6, CYP2C19, CYP2C19, CYP2C8, CYP2C9; 11 shared nodes; drug_interactions, pharmacokinetics

Show the evidence

Interaction statement

  • drug_interactions
    In vitro studies showed that tocilizumab has the potential to affect expression of multiple CYP enzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
  • drug_interactions
    Its effect on CYP2C8 or transporters is unknown.
  • drug_interactions
    In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of tocilizumab, respectively.
  • drug_interactions
    Exercise caution when coadministering TYENNE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.
  • pharmacokinetics
    Drug Interaction Studies In vitro data suggested that IL-6 reduced mRNA expression for several CYP450 isoenzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and this reduced expression was reversed by co-incubation with tocilizumab at clinically relevant concentrations.
  • pharmacokinetics
    Its effect on CYP2C8 or transporters (e.g., P-gp) is unknown.
2 more recorded rows
  • Interaction statement pharmacokinetics
    Caution should be exercised when TYENNE is coadministered with drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives (CYP3A4 substrates) [see Drug Interactions ( 7.2 )] .
  • Interaction statement pharmacokinetics
    Simvastatin Simvastatin is a CYP3A4 and OATP1B1 substrate.
  • CYP1A2
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Golodirsen, Tinidazole
  • CYP2B6
    FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Sofpironium, Bupropion, Golodirsen, Tinidazole, Naldemedine

CYP2C19

  • FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Naldemedine, Etravirine
  • FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Naldemedine, Etravirine
  • CYP2C8
    FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Golodirsen, Naldemedine, Methylnaltrexone, Lapatinib, Tivozanib
  • CYP2C9
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Tinidazole, Naldemedine
  • CYP2D6
    FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine

CYP3A4

  • FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
  • FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
  • OATP1B1
    FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Deoxycholic acid, Golodirsen, Naldemedine, Eravacycline
  • P-gp
    FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Vincristine

recorded 2026-07-23 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

CAS number
375823-41-9
RxCUI
2686045

Relations

Trade name
Tyenne, ACTEMRA, AVTOZMA
Also called
ATLIZUMAB, IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER, MRA
Development code
BAT-1806, BAT1806, BIIB-800, BIIB800, MSB-11456, MSB11456
Sources (5)

Sources

  • CLINICALTRIALS_SNAPSHOT K1:I031V2H011#aazg ·
  • ClinicalTrials.gov clinicaltrials.gov ·
  • drugsfda+ema drugsfda+ema ·
  • DailyMed label 87ac5047-4f2b-4571-a8a8-32e08865f379 ·
  • Drugs@FDA K1:I031V2H011#aazg ·

ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 3 required field(s) not terminal: Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 5 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.